InvestorsHub Logo
Followers 131
Posts 11471
Boards Moderated 0
Alias Born 01/06/2010

Re: None

Thursday, 09/28/2017 8:03:18 AM

Thursday, September 28, 2017 8:03:18 AM

Post# of 84
BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis
REUTERS 6:15 AM ET 9/28/2017

Sept 28 (Reuters) - Biovie Inc(BIVI)

* BioVie(BIVI) announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage:


Recent BIVI News